Adam L VanWert1, Douglas H Sweet. 1. Department of Pharmaceutical Sciences, Medical University of South Carolina, 280 Calhoun Street Rm. QE218, PO Box 250140, Charleston, South Carolina 29425, USA.
Abstract
PURPOSE: To elucidate the role of the renal basolateral transporter, Oat3, in the disposition of methotrexate. MATERIALS AND METHODS: Chinese hamster ovary cells expressing mouse Oat3 were used to determine kinetics and specificity of inhibition of methotrexate transport. Methotrexate clearance was then examined in vivo in wildtype and Oat3 knockout mice. RESULTS: NSAIDs, beta-lactams, and uremic toxins inhibited mOat3-mediated methotrexate uptake by 70-100%, while folate, leucovorin, and 5-methyltetrahydrofolate inhibited transport by 25-50%. A Km of 60.6 +/- 9.3 microM for methotrexate transport was determined. Oat3 knockout mice exhibited reduced methotrexate-to-inulin clearance ratios versus wildtype. Male wildtype mice, but not knockouts or females, demonstrated significantly accelerated methotrexate clearance in response to reduced folates. Reduced folates also markedly inhibited hepatic methotrexate accumulation in males, but not females, and the response was independent of Oat3 function. CONCLUSIONS: Oat3 contributes to methotrexate clearance, but represents only one component responsible for methotrexate's elimination. Therefore, in patients, dysfunctional hOAT3 polymorphisms or drug competition for hOAT3 transport may severely impact methotrexate elimination only when redundant means of methotrexate removal are also compromised. Furthermore, the present findings suggest that reduced-folate administration only influences methotrexate disposition in males, with the renal reduced-folate response influenced by OAT3 function.
PURPOSE: To elucidate the role of the renal basolateral transporter, Oat3, in the disposition of methotrexate. MATERIALS AND METHODS:Chinese hamster ovary cells expressing mouseOat3 were used to determine kinetics and specificity of inhibition of methotrexate transport. Methotrexate clearance was then examined in vivo in wildtype and Oat3 knockout mice. RESULTS: NSAIDs, beta-lactams, and uremic toxins inhibited mOat3-mediated methotrexate uptake by 70-100%, while folate, leucovorin, and 5-methyltetrahydrofolate inhibited transport by 25-50%. A Km of 60.6 +/- 9.3 microM for methotrexate transport was determined. Oat3 knockout mice exhibited reduced methotrexate-to-inulin clearance ratios versus wildtype. Male wildtype mice, but not knockouts or females, demonstrated significantly accelerated methotrexate clearance in response to reduced folates. Reduced folates also markedly inhibited hepatic methotrexate accumulation in males, but not females, and the response was independent of Oat3 function. CONCLUSIONS:Oat3 contributes to methotrexate clearance, but represents only one component responsible for methotrexate's elimination. Therefore, in patients, dysfunctionalhOAT3 polymorphisms or drug competition for hOAT3 transport may severely impact methotrexate elimination only when redundant means of methotrexate removal are also compromised. Furthermore, the present findings suggest that reduced-folate administration only influences methotrexate disposition in males, with the renal reduced-folate response influenced by OAT3 function.
Authors: Douglas H Sweet; Lauretta M S Chan; Ramsey Walden; Xiao-Ping Yang; David S Miller; John B Pritchard Journal: Am J Physiol Renal Physiol Date: 2002-12-17
Authors: Douglas H Sweet; David S Miller; John B Pritchard; Yuko Fujiwara; David R Beier; Sanjay K Nigam Journal: J Biol Chem Date: 2002-05-13 Impact factor: 5.157
Authors: Destiny Sykes; Douglas H Sweet; Simon Lowes; Sanjay K Nigam; John B Pritchard; David S Miller Journal: Am J Physiol Renal Physiol Date: 2003-12-23
Authors: Torben S Mikkelsen; Caroline F Thorn; Jun J Yang; Cornelia M Ulrich; Deborah French; Gianluigi Zaza; Henry M Dunnenberger; Sharon Marsh; Howard L McLeod; Kathy Giacomini; Mara L Becker; Roger Gaedigk; James Steven Leeder; Leo Kager; Mary V Relling; William Evans; Teri E Klein; Russ B Altman Journal: Pharmacogenet Genomics Date: 2011-10 Impact factor: 2.089
Authors: Courtney S Watts; Joseph N Sciasci; Jennifer L Pauley; John C Panetta; Deqing Pei; Cheng Cheng; Caroline M Christensen; Torben S Mikkelsen; Ching-Hon Pui; Sima Jeha; Mary V Relling Journal: J Pediatr Hematol Oncol Date: 2016-08 Impact factor: 1.289
Authors: Kazuto Yasuda; Cynthia Cline; Peter Vogel; Mihaela Onciu; Soghra Fatima; Brian P Sorrentino; Ranjit K Thirumaran; Sean Ekins; Yoshihiro Urade; Ko Fujimori; Erin G Schuetz Journal: Drug Metab Dispos Date: 2013-01-08 Impact factor: 3.922